A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults

NCT02390609 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Ibrutinib (Treatment A) [Reference]
DRUG: Ibrutinib (Treatment B)
DRUG: Ibrutinib (Treatment C)
DRUG: Ibrutinib (Treatment D)
DRUG: Ibrutinib (Treatment E)
DRUG: Ibrutinib (Treatment F)

Sponsor

Janssen Research & Development, LLC